Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Evotec is seeking a Lead In Silico Business Partner, Platform to act as the global front door between Drug Discovery Platforms and the In Silico & AI organization. You will own the relationship, demand, and roadmap while ensuring delivery across capability units with quality and value.
You will translate science priorities into in silico requirements, drive adoption, and contribute to client proposals with a commercial lens.
Job Title: Lead In Silico Business Partner, Platform
Job Type: Permanent
Location: Abingdon - UK, Alderley Park- UK or Verona, Italy
Our Company Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and the US. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies
The Lead In Silico Business Partner, Platform is the single front door between Evotec's Drug Discovery Platforms (DDP) segment and the global In Silico & AI organization, owning the relationship, the demand and the in silico roadmap for the segment worldwide. The role translates platform science priorities across DMPK, ADME/Tox, predictive and in vitro safety, hit identification and screening, biophysical and structural methods, bioanalysis, sample and reagent management and omics data generation into prioritized in silico and AI requirements, then orchestrates delivery across the capability units and holds it to quality, timing and measurable value. This is one of four Lead Business Partner seats in the newly established Strategy & Portfolio unit. It carries a commercial mandate alongside the scientific one: ADMET/Safety is one of three capabilities Evotec is industrializing as a differentiator, and this is the role that makes it land in the platform business.
FR : Dans le cadre de sa politique Diversité, Evotec étudie, à compétences égales, toutes les candidatures dont celles des personnes en situation de handicap.
EN: In the frame of our Diversity policy, Evotec considers, with equal competences, all applications including people with disabilities.
IT: In compliance with fundamental ethical and professional principles and with Legislative Decree 198/2006, Evotec is an Equal Opportunity Employer committed to fostering a safe, diverse, and inclusive workplace built on mutual respect. We provide equal employment opportunities to all qualified candidates and employees based on their skills, experience, and professional qualifications. In line with our ethical and professional principles, all employment‑related decisions, including recruitment and selection processes, are made fairly and without any form of discrimination. All qualified candidates will be considered for employment regardless of race, color, sex, age, disability, genetic information, gender expression, gender identity, nationality, religion, sexual orientation, or any other characteristic protected under applicable law.
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in‑class and best‑in‑class pharmaceutical products. Evotec leverages this “Data‑driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world‑leading co‑owned pipeline for innovative therapeutics and has to‑date established a portfolio of more than 200 proprietary and co‑owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.
For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Please click on the link below to access and review our Privacy Information for Applicants: Privacy Information for Applicants